The key role of gut–liver axis in pyrrolizidine alkaloid-induced hepatotoxicity and enterotoxicity

Jank, 2017, The risk of pyrrolizidine alkaloids in human food and animal feed, Trends Plant Sci, 22, 191, 10.1016/j.tplants.2017.01.002 Robertson, 2017, Pyrrolizidine alkaloids: occurrence, biology, and chemical synthesis, Nat Prod Rep, 34, 62, 10.1039/C5NP00076A Lin, 2011, Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum, J Hepatol, 54, 666, 10.1016/j.jhep.2010.07.031 Zhu, 2021, Tu-San-Qi (Gynura japonica): the culprit behind pyrrolizidine alkaloid-induced liver injury in China, Acta Pharmacol Sin, 42, 1212, 10.1038/s41401-020-00553-9 Prakash, 1999, Pyrrolizidine alkaloids in human diet, Mutat Res Genet Toxicol, 443, 53, 10.1016/S1383-5742(99)00010-1 He, 2021, Mutational signature analysis reveals widespread contribution of pyrrolizidine alkaloid exposure to human liver cancer, Hepatology, 74, 264, 10.1002/hep.31723 Ruan, 2014, Metabolic activation of pyrrolizidine alkaloids: insights into the structural and enzymatic basis, Chem Res Toxicol, 27, 1030, 10.1021/tx500071q Ma, 2019, Pyrrole–hemoglobin adducts, a more feasible potential biomarker of pyrrolizidine alkaloid exposure, Chem Res Toxicol, 32, 1027, 10.1021/acs.chemrestox.8b00369 Lin, 1998, Microsomal formation of a pyrrolic alcohol glutathione conjugate of clivorine firm evidence for the formation of a pyrrolic metabolite of an otonecine-type pyrrolizidine alkaloid, Drug Metab Dispos, 26, 181 Lame, 1995, Biliary excretion of pyrrolic metabolites of [14C]monocrotaline in the rat, Drug Metab Dispos, 23, 422 He, 2021, Lung injury induced by pyrrolizidine alkaloids depends on metabolism by hepatic cytochrome P450s and blood transport of reactive metabolites, Arch Toxicol, 95, 103, 10.1007/s00204-020-02921-0 Song, 2020, Pulmonary toxicity is a common phenomenon of pyrrolizidine alkaloids, J Environ Sci Health C, 38, 124 Nolan, 2010, The role of intestinal endotoxin in liver injury: a long and evolving history, Hepatology, 52, 1829, 10.1002/hep.23917 Ng, 2017, Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies, Lancet, 390, 2769, 10.1016/S0140-6736(17)32448-0 Mawdsley, 2005, Psychological stress in IBD: new insights into pathogenic and therapeutic implications, Gut, 54, 1481, 10.1136/gut.2005.064261 Dieleman, 1998, Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines, Clin Exp Immunol, 114, 385, 10.1046/j.1365-2249.1998.00728.x Thaker, 2012, Modeling colitis-associated cancer with azoxymethane (AOM) and dextran sulfate sodium (DSS), 67 Williams, 2016, Intestinal preparation techniques for histological analysis in the mouse, Curr Protoc Mouse Biol, 6, 148, 10.1002/cpmo.2 Nadatani, 2012, High mobility group box 1 promotes small intestinal damage induced by nonsteroidal anti-inflammatory drugs through Toll-like receptor 4, Am J Pathol, 181, 98, 10.1016/j.ajpath.2012.03.039 Cani, 2008, Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice, Diabetes, 57, 1470, 10.2337/db07-1403 Gu, 2003, Liver-specific deletion of the NADPH-cytochrome P450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase, J Biol Chem, 278, 25895, 10.1074/jbc.M303125200 Zhang, 2009, An intestinal epithelium-specific cytochrome P450 (P450) reductase-knockout mouse model: direct evidence for a role of intestinal p450s in first-pass clearance of oral nifedipine, Drug Metab Dispos, 37, 651, 10.1124/dmd.108.025429 Fan, 2020, Hepatic and intestinal biotransformation gene expression and drug disposition in a dextran sulfate sodium-induced colitis mouse model, Acta Pharm Sin B, 10, 123, 10.1016/j.apsb.2019.12.002 Ruan, 2015, Blood pyrrole–protein adducts--a biomarker of pyrrolizidine alkaloid-induced liver Injury in humans, J Environ Sci Health C, 33, 404, 10.1080/10590501.2015.1096882 DeLeve, 1999, Characterization of a reproducible rat model of hepatic veno-occlusive disease, Hepatology, 29, 1779, 10.1002/hep.510290615 Angulo, 2007, The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD, Hepatology, 45, 846, 10.1002/hep.21496 Rahman, 2006, Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method, Nat Protoc, 1, 3159, 10.1038/nprot.2006.378 Linden, 2008, Mucins in the mucosal barrier to infection, Mucosal Immunol, 1, 183, 10.1038/mi.2008.5 Huxtable, 1996, Physicochemical and metabolic basis for the differing neurotoxicity of the pyrrolizidine alkaloids, trichodesmine and monocrotaline, Neurochem Res, 21, 141, 10.1007/BF02529131 Mattocks, 1990, Trapping and measurement of short-lived alkylating-agents in a recirculating flow system, Chem Biol Interact, 76, 19, 10.1016/0009-2797(90)90031-H Chan, 1994, Toxicity and carcinogenicity of riddelliine following 13 weeks of treatment to rats and mice, Toxicon, 32, 891, 10.1016/0041-0101(94)90368-9 Yang, 2016, Cytotoxicity of pyrrolizidine alkaloid in human hepatic parenchymal and sinusoidal endothelial cells: firm evidence for the reactive metabolites mediated pyrrolizidine alkaloid-induced hepatotoxicity, Chem Biol Interact, 243, 119, 10.1016/j.cbi.2015.09.011 Spolarics, 1996, Endotoxin stimulates gene expression of ROS-eliminating pathways in rat hepatic endothelial and Kupffer cells, Am J Physiol, 270, G660 Pompella, 2003, The changing faces of glutathione, a cellular protagonist, Biochem Pharmacol, 66, 1499, 10.1016/S0006-2952(03)00504-5 He, 2020, Comprehensive investigation and risk study on pyrrolizidine alkaloid contamination in Chinese retail honey, Environ Pollut, 267, 115542, 10.1016/j.envpol.2020.115542 Singh, 2015, Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis, Cochrane Database Syst Rev, 11, CD001176 van Deventer, 1997, Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group, Gastroenterology, 113, 383, 10.1053/gast.1997.v113.pm9247454 Ding, 2003, Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts, Annu Rev Pharmacol Toxicol, 43, 149, 10.1146/annurev.pharmtox.43.100901.140251 Xie, 2016, An update on the role of intestinal cytochrome P450 enzymes in drug disposition, Acta Pharm Sin B, 6, 374, 10.1016/j.apsb.2016.07.012 Yang, 2020, Absorption difference between hepatotoxic pyrrolizidine alkaloids and their N-oxides - mechanism and its potential toxic impact, J Ethnopharmacol, 249, 112421, 10.1016/j.jep.2019.112421 Rao, 2009, Endotoxemia and gut barrier dysfunction in alcoholic liver disease, Hepatology, 50, 638, 10.1002/hep.23009 Altin, 1988, Non-parenchymal cells as mediators of physiological responses in liver, Mol Cell Biochem, 83, 3, 10.1007/BF00223193 Crispe, 2009, The liver as a lymphoid organ, Annu Rev Immunol, 27, 147, 10.1146/annurev.immunol.021908.132629 Racanelli, 2006, The liver as an immunological organ, Hepatology, 43, S54, 10.1002/hep.21060 Knook, 1980, Isolated parenchymal, Kupffer and endothelial rat liver cells characterized by their lysosomal enzyme content, Biochem Biophys Res Commun, 96, 250, 10.1016/0006-291X(80)91207-3 Smedsrod, 1997, Advanced glycation end products are eliminated by scavenger-receptor-mediated endocytosis in hepatic sinusoidal Kupffer and endothelial cells, Biochem J, 322, 567, 10.1042/bj3220567 Masubuchi, 2008, Down-regulation of hepatic cytochrome P450 enzymes in rats with trinitrobenzene sulfonic acid-induced colitis, Drug Metab Dispos, 36, 597, 10.1124/dmd.107.018754 Dai, 2010, Retrorsine, but not monocrotaline, is a mechanism-based inactivator of P450 3A4, Chem Biol Interact, 183, 49, 10.1016/j.cbi.2009.10.001 Droge, 2002, Free radicals in the physiological control of cell function, Physiol Rev, 82, 47, 10.1152/physrev.00018.2001